Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Más filtros











Intervalo de año de publicación
1.
Barcelona; Elsevier; 17a ed; 2012. 2 v p. 2539.
Monografía en Español | BVSNACUY | ID: bnu-16728

Asunto(s)
Medicina Interna
6.
Madrid; Elsevier; 15a.ed.; 2004. 1428 p.
Monografía en Español | URUGUAIODONTO | ID: odn-3039

Asunto(s)
Medicina Interna
7.
Madrid; Elsevier; 15a.ed.; 2004. 1358 p.
Monografía en Español | URUGUAIODONTO | ID: odn-3038

Asunto(s)
Medicina Interna
14.
Leuk Lymphoma ; 1(1): 47-9, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-27456407

RESUMEN

We report a patient born in a non-endemic area for human T-lymphotropic virus type I (HTLV-I) infection, in whom an adult T-cell leukemia (ATL) was diagnosed. After the development of acute symptomatic hypercalcemia, treatment with 2-deoxycoformycin was administered. Only mild side-effects were observed, and after treatment a long-lasting complete remission was achieved. The epidemiology of HTLV-I infection and the treatment of ATL are discussed.

16.
Rev Bras Pesqui Med Biol ; 12(2-3): 197-206, 1979 Jun.
Artículo en Español | MEDLINE | ID: mdl-42120

RESUMEN

A review of the present results of bone-marrow transplantation (B.M.T.) in severe aplastic anaemia is presented. Nowadays, there is little doubt that for patients with severe aplastic anaemia the treatment of choice is the B.M.T. provided always that a suitable donor exists. If the patient is fortunate enough to have a normal identical twin, the syngeneic B.M.T. without immunosuppresive conditioning must be performed. This is usually successful, though in some patients failures can be observed due to probable immunological interference. This can be overcome by a new syngeneic B.M.T. preceded by immunosuppression. The usual type of suitable donors is an HLA-identical (including locus D) sibling (allogeneic B.M.T.). Approximately 50% of patients treated in this way can become long-term survivors. The chief complications causing mortality from the allogeneic B.M.T. are graft rejection and graft-versus-host-disease (G.V.H.D.). In order to reduce the graft rejection rate, transfusions from marrow-donor and relatives prior to the transplantation should be avoided. Other probable factor influencing the final outcome of the allogeneic B.M.T. are the interval diagnosis-transplantation, age of the patient, marrow cell dose, the difference of sex between the donor and the recipients and others. Semi-incompatible and incompatible allogeneic B.M.T. are briefly considered.


Asunto(s)
Anemia Aplásica/terapia , Trasplante de Médula Ósea , Factores de Edad , Anemia Aplásica/mortalidad , Transfusión Sanguínea , Femenino , Rechazo de Injerto , Reacción Injerto-Huésped , Histocompatibilidad , Humanos , Terapia de Inmunosupresión , Masculino , Factores Sexuales , Trasplante Homólogo , Trasplante Isogénico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA